COVID-19 vaccine approved for trials, says Chinese military
The Chinese Ministry of National Defense (MND) announced on 18 March that a vaccine for the COVID-19 coronavirus, developed by the Academy of Military Medical Sciences of the People’s Liberation Army (PLA), has been approved for clinical trials.
The subunit vaccine has apparently been approved for safe testing on humans by an undisclosed (and therefore unverified) third party.
Preparations for mass production of the vaccine are also under way, the MND stated.
The team of PLA scientists worked under senior bioengineer Maj Gen Chen Wei. He has been conducting research in Wuhan, where the COVID-19 outbreak began.
A subunit vaccination includes a fragment of the pathogen that can initiate an immune response.
More from Defence Notes
-
Spain unveils new multi-billion euro defence investment plan
The new plan outlined how Spain would reach 2% of its GDP spend on defence by 2025, with €1.9 billion earmarked for new equipment acquisition with several land, naval and air platforms disclosed to be replaced or upgraded.
-
New Zealand boosts defence spend to US$6.6 billion and vows increased closeness with Australia
This budget will be spent over the next four years and nearly doubles the country’s defence spending as part of GDP to 2%.
-
UK Chancellor commits £2 billion to make the country a “defence industrial superpower”
Rachel Reeves announced port upgrades, protected budgets for innovation and investment in novel technologies.
-
Avalon 2025: Australian defence budget meets the low expectations of show attendees
The Australian Budget was marked by tax cuts and a looming general election which led to little hope that there would be a substantial defence boost even with a big bill for nuclear submarines due.
-
Launch of Gilat Defense targets DoD market
The communications company Gilat launched its new Gilat Defense division at the Satellite 2025 expo, with future solutions aimed at US military customers.